VLUE vs. VTV: Does the Value Factor Beat Just Buying Vanguard's Value ETF?

VLUE (iShares MSCI USA Enhanced Value) returned 71.64% over the past year vs VTV (Vanguard Value) at 25.63%, driven by a different “value” definition and strong exposure to cyclical tech/semis. VLUE’s top weights are Micron (11.60%) and Intel (9.26%), with ~31.5% in semiconductors/tech hardware, contributing to YTD outperformance through July 13 of +42.82% vs VTV’s +16.07%. VTV’s higher forward dividend ($4.3272 vs VLUE’s $2.7886) and diversified mega-cap tilt may support steadier income, while VLUE carries higher concentration and potential reversal risk if chips “roll over” or factor screens rotate.

Analysis

VLUE is effectively a concentrated bet on whether the market keeps paying for “cheap” cyclical tech rather than boring financial/healthcare value. That makes it more fragile than it looks: if semiconductor multiples compress even modestly, the fund can give back a large share of its relative gains because a small set of names drives a disproportionate amount of index behavior. VTV, by contrast, is a cleaner core-value vehicle with lower dispersion and a much better income profile, so it should hold up better in a risk-off tape or if factor leadership broadens away from chips.

The near-term catalyst is not macro value rotation in the abstract; it is the next 1-3 months of guidance from memory, hardware, and fab-equipment names that dominate VLUE’s marginal return stream. If inventory digestion or AI-capex expectations soften, the ETF’s sector-neutral design becomes a liability because the rebalance mechanism will keep forcing capital into whatever screen is statistically cheapest, even if the fundamental thesis is deteriorating. If those companies instead keep revising up, VLUE can continue to outperform, but that is a momentum outcome masquerading as value exposure.

The contrarian point is that the market may be overrating VLUE’s recent outperformance as evidence of superior “value” selection when it is mostly a narrow cyclical bet. Consensus seems to be underappreciating tracking-error risk: investors buying it as a core value sleeve are implicitly expressing a view on semis, not value broadly. For long-horizon allocators, the bigger question is whether they want factor purity or balance-sheet quality and yield; in this setup, VTV looks like the more durable core, while VLUE is a trade on continued chip-cycle reflation.

Key Decisions for Investors

• Relative-value trade: long VTV / short VLUE for the next 1-3 months if you expect semiconductor momentum to fade; the setup benefits from VLUE’s concentration risk and should work if MU/INTC/AMAT guidance merely meets, rather than beats. Falsify if VLUE keeps outperforming VTV by another ~5-7 percentage points on renewed chip strength.
• Use VTV as the core value allocation and keep VLUE as a small satellite only. The risk/reward is better in VTV because it is less dependent on a single factor sub-basket; this is especially attractive for risk budgets that cannot tolerate ETF-level tracking error.
• Watch MU, INTC, AMAT, and WDC earnings as the real catalyst path, not ETF flows. If inventory and pricing data roll over, add to the VTV-over-VLUE relative short; if gross margins and bookings improve, cover and reassess because VLUE’s concentration can keep working longer than expected.
• For tactical accounts that want to express continued value-factor momentum, buy VLUE only on post-earnings weakness in semis and pair it against a market hedge. That limits the chance of paying peak relative multiple for a trade that is actually dependent on the cycle.